CN111686236B - 一种解酒保肝护脑胶囊 - Google Patents
一种解酒保肝护脑胶囊 Download PDFInfo
- Publication number
- CN111686236B CN111686236B CN202010682712.1A CN202010682712A CN111686236B CN 111686236 B CN111686236 B CN 111686236B CN 202010682712 A CN202010682712 A CN 202010682712A CN 111686236 B CN111686236 B CN 111686236B
- Authority
- CN
- China
- Prior art keywords
- parts
- vitamin
- extract
- cysteine
- silymarin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims abstract description 18
- 210000004185 liver Anatomy 0.000 title claims abstract description 18
- 210000004556 brain Anatomy 0.000 title claims abstract description 13
- 230000000694 effects Effects 0.000 title claims description 18
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 40
- 239000000284 extract Substances 0.000 claims abstract description 35
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 22
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 claims abstract description 21
- 240000008042 Zea mays Species 0.000 claims abstract description 21
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 21
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 21
- 235000005822 corn Nutrition 0.000 claims abstract description 21
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 claims abstract description 21
- 229960004245 silymarin Drugs 0.000 claims abstract description 21
- 235000017700 silymarin Nutrition 0.000 claims abstract description 21
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 20
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 20
- 239000011718 vitamin C Substances 0.000 claims abstract description 20
- 241000244938 Penthorum chinense Species 0.000 claims abstract description 19
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims abstract description 18
- 230000002075 anti-alcohol Effects 0.000 claims abstract description 17
- 235000011347 Moringa oleifera Nutrition 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 13
- 229930003270 Vitamin B Natural products 0.000 claims abstract description 9
- 235000019156 vitamin B Nutrition 0.000 claims abstract description 9
- 239000011720 vitamin B Substances 0.000 claims abstract description 9
- 241000220215 Moringa Species 0.000 claims description 14
- 238000011049 filling Methods 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 244000005700 microbiome Species 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 238000004806 packaging method and process Methods 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 229940082477 moringa oleifera leaf extract Drugs 0.000 claims description 5
- 235000013878 L-cysteine Nutrition 0.000 claims description 3
- 239000004201 L-cysteine Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims 6
- 239000008187 granular material Substances 0.000 claims 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 abstract description 14
- 231100000419 toxicity Toxicity 0.000 abstract description 4
- 230000001988 toxicity Effects 0.000 abstract description 4
- 244000179886 Moringa oleifera Species 0.000 abstract 1
- 239000000047 product Substances 0.000 description 24
- 239000000203 mixture Substances 0.000 description 13
- 238000009472 formulation Methods 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 239000003814 drug Substances 0.000 description 9
- 206010019133 Hangover Diseases 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229930003451 Vitamin B1 Natural products 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000035622 drinking Effects 0.000 description 5
- 230000035987 intoxication Effects 0.000 description 5
- 231100000566 intoxication Toxicity 0.000 description 5
- 229960003495 thiamine Drugs 0.000 description 5
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 5
- 235000010374 vitamin B1 Nutrition 0.000 description 5
- 239000011691 vitamin B1 Substances 0.000 description 5
- 210000005229 liver cell Anatomy 0.000 description 4
- 235000013305 food Nutrition 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- KJXSIXMJHKAJOD-LSDHHAIUSA-N (+)-dihydromyricetin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC(O)=C(O)C(O)=C1 KJXSIXMJHKAJOD-LSDHHAIUSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 201000007930 alcohol dependence Diseases 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011946 reduction process Methods 0.000 description 2
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000006264 Korsakoff syndrome Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241000219099 Parthenocissus quinquefolia Species 0.000 description 1
- 235000009388 Parthenocissus quinquefolia Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 235000021403 cultural food Nutrition 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- KQILIWXGGKGKNX-UHFFFAOYSA-N dihydromyricetin Natural products OC1C(=C(Oc2cc(O)cc(O)c12)c3cc(O)c(O)c(O)c3)O KQILIWXGGKGKNX-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000004203 pancreatic function Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000008433 psychological processes and functions Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Medical Informatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及解酒保肝护脑胶囊，可有效地减少酒精和乙醛对身体的毒害，尤其是保护肝脏和大脑，其解决的技术方案是，该解酒保肝护脑胶囊是由以下重量份数计的原料制成：辣木叶提取物1‑20份、赶黄草提取物1‑20份、玉米肽15‑55份、水飞蓟素1‑20份、L‑半胱氨酸15‑55份、维生素C 1‑20份和维生素B1 0.1‑5份，本发明有效地减少因饮酒产生的不适症状、养护肝脏和保护大脑，是解酒保肝护脑产品上的创新。
Description
技术领域
本发明涉及食品技术领域，特别是一种解酒保肝护脑胶囊。
背景技术
酒精即乙醇，其在人体内的代谢过程如下：肝脏是乙醇的主要代谢场所，乙醇经过乙醇脱氢酶脱氢而生成乙醛；乙醛由肝细胞线粒体内的乙醛脱氢酶脱氢生成乙酸；乙酸可在体内转化成乙酰辅酶A，该物质进入三羧酸循环后被氧化分解为二氧化碳和水，然后排除体外。这其中乙醛对人体肝脏、胰脏、肾脏功能的损伤最为严重。
中国自夏朝开始发明了酒，并在几千年的历史中形成了独特的中国酒文化，是中华民族饮食文化的—个重要组成部分，酒作为一种物质文化，其形态多种多样；而饮酒成为中国人社交聚会的必要环节，彰显了它的精神文化价值，也正因为如此，导致了众多因为酒精而引起的慢性疾病，特别是肝脏疾病，据报道，我国有近1亿酒精性肝病患者，包括酒精性肝硬化，酒精性肝炎，酒精性脂肪肝，轻症酒精性肝损伤等。酒精及其代谢产物乙醛可对神经组织造成直接或间接的损害，长期滥饮酒可伴有脑损害及相应的心理功能改变，酒依赖严重的神经系统损害后果是Korsakoff综合征,其特点是记忆缺陷；最明显的是顺行性遗忘及许多其它认知损害。目前还没有针对这些酒精性疾病的特效药物和治疗手段。
中国传统的解酒药包括葛花、葛根、枳椇子、陈皮、藤茶等中药材，以及保肝中药食材如水飞蓟、灵芝、人参、蜂蜜等。但是这些中药食材的解酒效果都不甚明显，而且个体反应差别大，不能起到普遍性的解酒作用。据国内外报道，N-乙酰-L-半胱氨酸和L-半胱氨酸能通过结合乙醛起到解酒的作用，其它报道能解酒的分子或混合物包括L-阿拉伯糖、姜黄素、水飞蓟素、小分子玉米肽、牡蛎肽、二氢杨梅素等。但迄今为止，国内外尚未研发出一种普遍适用且具有明显效果的解酒产品，用它来解酒精之毒（特别是解乙醛之毒）从而达到保肝护脑的目的。
发明内容
针对上述情况，为解决现有技术之缺陷，本发明之目的就是提供一种解酒保肝护脑胶囊，可有效地减少酒精和乙醛对身体的毒害，尤其是保护肝脏和大脑。
本发明解决的技术方案是，该解酒保肝护脑胶囊是由以下重量份数计的原料制成：辣木叶提取物1-20份、赶黄草提取物1-20份、玉米肽15-55份、水飞蓟素1-20份、L-半胱氨酸15-55份、维生素C 1-20份和维生素B1 0.1-5份，按配方称取微生物含量合格的辣木叶提取物、赶黄草提取物、玉米肽、水飞蓟素、L-半胱氨酸、维生素C、维生素B1，将上述原料置于混合机中充分混合，然后干燥、整粒、灌注胶囊，包装，即得。
本发明还可利用成熟的工艺技术制成其它固体制剂或液体制剂。
本发明结合纯植物提取物和小分子解酒成分，通过反复的配方研究及动物试验，成功地开发出具有明显解酒保肝护脑的配方和制备方法，本发明产品的成功上市将为广大饮酒爱好者带来福音，在满足日常应酬的同时，有效地减少因饮酒产生的不适症状、养护肝脏和保护大脑，是解酒保肝护脑产品上的创新。
附图说明
图1为本发明各组小鼠醉酒耐受时间实验结果图，其中阳性药为市售某知名国产解酒产 品；配方1为实施例1所制备的产品；配方2为实施例2所制备的产品；配方3为实施例3 所制备的产品(
n＝10，*p<0.05，**p<0.01，***p<0.001)。
图2为本发明各组醉酒小鼠解酒时间的实验结果图，其中阳性药为市售某知名国产解酒 产品；配方1为实施例1所制备的产品；配方2为实施例2所制备的产品；配方3为实施例 3所制备的产品(
n＝10，*p<0.05，**p<0.01，***p<0.001)。
具体实施方式
以下结合实施例对本发明的具体实施方式作进一步详细说明。
实施例1
本发明在具体实施时，可由以下重量份数计的原料制成：辣木叶提取物10份、赶黄草提取物10份、玉米肽32份、水飞蓟素10份、L-半胱氨酸28份、维生素C 8.5份和维生素B11.5份，按配方称取微生物含量合格的辣木叶提取物、赶黄草提取物、玉米肽、水飞蓟素、L-半胱氨酸、维生素C、维生素B1，将上述原料置于混合机中充分混合，然后干燥、整粒、灌注胶囊，包装，即得；根据上述配方制备的胶囊剂为配方1。
实施例2
本发明在具体实施时，可由以下重量份数计的原料制成：辣木叶提取物13份、赶黄草提取物11份、玉米肽29份、水飞蓟素9份、L-半胱氨酸25份、维生素C 12份和维生素B1 1份，按配方称取微生物含量合格的辣木叶提取物、赶黄草提取物、玉米肽、水飞蓟素、L-半胱氨酸、维生素C、维生素B1，将上述原料置于混合机中充分混合，然后干燥、整粒、灌注胶囊，包装，即得；根据上述配方制备的胶囊剂为配方2。
实施例3
本发明在具体实施时，可由以下重量份数计的原料制成：辣木叶提取物11份、赶黄草提取物13份、玉米肽28份、水飞蓟素8份、L-半胱氨酸24份、维生素C 15.5份和维生素B10.5份，按配方称取微生物含量合格的辣木叶提取物、赶黄草提取物、玉米肽、水飞蓟素、L-半胱氨酸、维生素C、维生素B1，将上述原料置于混合机中充分混合，然后干燥、整粒、灌注胶囊，包装，即得；根据上述配方制备的胶囊剂为配方3。
本发明组方中，辣木叶提取物具有解酒、抗氧化、降血糖、降血脂的作用，长期食用可增强人体免疫力、延缓衰老、预防疾病。赶黄草提取物具有解酒和保护肝脏的作用。玉米肽具有抑制酒精中毒和降压的作用。水飞蓟素具有强力的抗氧化功能，能保护肝脏细胞免受自由基破坏，效力远胜于维生素E，还可促进蛋白质的合成，加快制造新的肝脏细胞，使已受损的肝脏细胞自行修复，另外水飞蓟素具有抗辐射、抗衰老、防治动脉硬化、延缓皮肤老化等功效。L-半胱氨酸是一种氨基酸类解毒药，它参与细胞的还原过程和肝脏内的磷脂代谢，有保护肝细胞不受损害、促进肝脏功能恢复和旺盛的药理效应，维生素C在体内氧还原过程中发挥着重要的作用，能抗氧化、解毒，是常用的膳食补充剂，由于饮酒导致体内维生素B1浓度下降，补充维生素B1会帮助解酒过程。据以上原理，本发明通过反复实验，得到具有解酒保肝护脑的产品，其效果经小鼠实验得到了充分证明，相关实验资料如下：
1、本发明产品在小鼠醉酒耐受和解酒的作用
1.1实验方法：KM小鼠(雄性，18～22g，SPF级)50只，分别为模型组、阳性药组、配方1组、配方2组、配方3组，每组10只，其中阳性药为市售某知名国产解酒产品；配方1为本发明实施例1所制备的产品；配方2为本发明实施例2所制备的产品；配方3为本发明实施例3所制备的产品；小鼠禁食不禁水 12 小时后，给药组（给药剂量为人体剂量的30倍）分别给药（0.2mL/10g），模型组代以等容积生理盐水，30 min后，各组均以 56％(V/V)红星二锅头白酒（0.15mL/10g）灌服。观察记录小鼠的一般情况，计算出致醉率、小鼠24小时生存率、醉酒耐受时间和解酒时间。
1.2实验结果：
表1、实验小鼠致醉率和24小时生存率
| 分组 | 模型组 | 阳性药组 | 配方1组 | 配方2组 | 配方3组 |
| 致醉率% | 100 | 90 | 100 | 100 | 90 |
| 24小时生存率% | 100 | 100 | 100 | 100 | 90 |
本发明小鼠醉酒耐受时间实验结果如图1所示，本发明实施例1、2、3制得的产品耐受时间显著高于模型组。
本发明醉酒小鼠解酒时间实验结果如图2所示，本发明实施例1、2、3制得的产品解酒时间显著快于模型组和阳性药组。
经反复实验，由本发明其他实施例制得的产品均能取得和以上实验结果相同或相近似的有益效果。
以上实验结果表明，本发明能显著延长实验小鼠的醉酒时间，并且能显著加速醉酒小鼠的解酒，本发明产品通过解酒毒，抗氧化达到养护肝脏和保护大脑的作用，具有良好的推广和应用价值。
Claims (4)
1.一种解酒保肝护脑胶囊，其特征在于，该解酒保肝护脑胶囊是由以下重量份数计的原料制成：辣木叶提取物1-13份、赶黄草提取物1-13份、玉米肽28-55份、水飞蓟素1-10份、L-半胱氨酸24-55份、维生素C 1-15.5份和维生素B1 0.5-5份，所述辣木叶提取物、赶黄草提取物、玉米肽、水飞蓟素、L-半胱氨酸、维生素C和维生素B1的用量比例为辣木叶提取物∶赶黄草提取物∶玉米肽∶水飞蓟素∶L-半胱氨酸∶维生素C∶维生素B1=10-13∶10-13∶28-32∶8-10∶24-28∶8.5-15.5∶0.5-1.5，按配方称取微生物含量合格的辣木叶提取物、赶黄草提取物、玉米肽、水飞蓟素、L-半胱氨酸、维生素C、维生素B1，将上述原料置于混合机中充分混合，然后干燥、整粒、灌注胶囊，包装，即得。
2.根据权利要求1所述的解酒保肝护脑胶囊，其特征在于，由以下重量份数计的原料制成：辣木叶提取物10份、赶黄草提取物10份、玉米肽32份、水飞蓟素10份、L-半胱氨酸28份、维生素C 8.5份和维生素B1 1.5份，按配方称取微生物含量合格的辣木叶提取物、赶黄草提取物、玉米肽、水飞蓟素、L-半胱氨酸、维生素C、维生素B1，将上述原料置于混合机中充分混合，然后干燥、整粒、灌注胶囊，包装，即得。
3.根据权利要求1所述的解酒保肝护脑胶囊，其特征在于，由以下重量份数计的原料制成：辣木叶提取物13份、赶黄草提取物11份、玉米肽29份、水飞蓟素9份、L-半胱氨酸25份、维生素C 12份和维生素B1 1份，按配方称取微生物含量合格的辣木叶提取物、赶黄草提取物、玉米肽、水飞蓟素、L-半胱氨酸、维生素C、维生素B1，将上述原料置于混合机中充分混合，后干燥、整粒、灌注胶囊，包装，即得。
4.根据权利要求1所述的解酒保肝护脑胶囊，其特征在于，由以下重量份数计的原料制成：辣木叶提取物11份、赶黄草提取物13份、玉米肽28份、水飞蓟素8份、L-半胱氨酸24份、维生素C 15.5份和维生素B1 0.5份，按配方称取微生物含量合格的辣木叶提取物、赶黄草提取物、玉米肽、水飞蓟素、L-半胱氨酸、维生素C、维生素B1，将上述原料置于混合机中充分混合，然后干燥、整粒、灌注胶囊，包装，即得。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010682712.1A CN111686236B (zh) | 2020-07-15 | 2020-07-15 | 一种解酒保肝护脑胶囊 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010682712.1A CN111686236B (zh) | 2020-07-15 | 2020-07-15 | 一种解酒保肝护脑胶囊 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111686236A CN111686236A (zh) | 2020-09-22 |
| CN111686236B true CN111686236B (zh) | 2023-07-14 |
Family
ID=72485708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010682712.1A Active CN111686236B (zh) | 2020-07-15 | 2020-07-15 | 一种解酒保肝护脑胶囊 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111686236B (zh) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20020004193A (ko) * | 2000-07-03 | 2002-01-16 | 박명환 | 알콜 흡수 억제제를 함유한 숙취 제거 및 간장 보호용조성물 |
| CN107348299A (zh) * | 2017-07-31 | 2017-11-17 | 湖州金诺康健康科技有限公司 | 一种具有护肝解酒功效的固体饮料 |
| CN107518133A (zh) * | 2017-09-29 | 2017-12-29 | 芜湖绿而优农业科技有限公司 | 一种解酒护肝花茶及其制备方法 |
| CN107551001A (zh) * | 2017-09-07 | 2018-01-09 | 浙江省中医药研究院 | 一种用于防治酒精性肝损伤的中药复合物及其制法 |
| CN109122856A (zh) * | 2018-07-05 | 2019-01-04 | 乙丙丁健康产业（深圳）有限公司 | 一种护肝醒酒中药组合物 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070202215A1 (en) * | 2006-02-28 | 2007-08-30 | Zahramehran Salari Lak | Dietary nutritional supplements for persons consuming alcohol products |
| US9603830B2 (en) * | 2014-05-29 | 2017-03-28 | Thriveplus Llc | Compositions and methods for preventing and recovery from detrimental effects of alcohol consumption |
-
2020
- 2020-07-15 CN CN202010682712.1A patent/CN111686236B/zh active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20020004193A (ko) * | 2000-07-03 | 2002-01-16 | 박명환 | 알콜 흡수 억제제를 함유한 숙취 제거 및 간장 보호용조성물 |
| CN107348299A (zh) * | 2017-07-31 | 2017-11-17 | 湖州金诺康健康科技有限公司 | 一种具有护肝解酒功效的固体饮料 |
| CN107551001A (zh) * | 2017-09-07 | 2018-01-09 | 浙江省中医药研究院 | 一种用于防治酒精性肝损伤的中药复合物及其制法 |
| CN107518133A (zh) * | 2017-09-29 | 2017-12-29 | 芜湖绿而优农业科技有限公司 | 一种解酒护肝花茶及其制备方法 |
| CN109122856A (zh) * | 2018-07-05 | 2019-01-04 | 乙丙丁健康产业（深圳）有限公司 | 一种护肝醒酒中药组合物 |
Non-Patent Citations (2)
| Title |
|---|
| 赶黄草总黄酮的提取及其对小鼠酒精性肝损伤的治疗作用;雷斯瑀 等;《吉林畜牧兽医》;20181231;第39卷(第6期);5-8,11 * |
| 辣木源多肽组分改善D-半乳糖致衰小鼠氧化损伤作用;耿春阳 等;《食品科学》;20191012;1-9 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111686236A (zh) | 2020-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102802636B (zh) | 藏花素水解产物 | |
| TWI721248B (zh) | 提高耐力表現之抗疲勞組合物 | |
| KR102107387B1 (ko) | 흑삼 추출물을 함유하는 숙취해소용 음료 조성물 | |
| KR20170135520A (ko) | 더덕 추출물을 함유하는 장 건강 개선용 조성물 | |
| KR20200120465A (ko) | 숙취해소에 뛰어나며 알코올에 의한 간 손상을 예방 또는 치료용 조성물 | |
| KR101687982B1 (ko) | 정자수 증가와 환경호르몬 예방효과를 갖는 성기능 개선용 조성물 및 그의 제조방법 | |
| CN112569323A (zh) | 一种解酒护肝的组合物及其应用 | |
| CN106376917A (zh) | 一种从多方面调节情绪的保健食品或饮料配方 | |
| CN112021572A (zh) | 一种醒酒保肝保健食品及其制备方法 | |
| CN103203008A (zh) | 用于解酒的药物组合物及其制备方法 | |
| KR101729003B1 (ko) | 황칠 추출물 또는 황칠액 발효대사체를 포함하는 통풍 예방 또는 치료용 조성물 | |
| KR20020092082A (ko) | 자양강장제 조성물 | |
| JP2009013083A (ja) | 経口投与組成物 | |
| CN112618608A (zh) | 具有解酒功能的组合物及其制备方法和应用 | |
| CN104739964B (zh) | 一种蜗牛解酒制剂及其制作方法 | |
| CN111686236B (zh) | 一种解酒保肝护脑胶囊 | |
| CN111066994A (zh) | 一种解酒护肝功能饮料及其制备方法 | |
| CN116076710A (zh) | 一种具有抗衰美白功能的玫瑰本草酵素及其制备方法和应用 | |
| KR102151373B1 (ko) | 발효 노니를 포함하는 알러지 예방 및 개선용 식품 조성물 및 그 제조방법 | |
| KR101935861B1 (ko) | 숙취해소 및 간 기능 개선용 건강 기능성 식품 조성물 및 이의 제조 방법 | |
| KR101093006B1 (ko) | 미생물을 이용한 우황 청심원 원료 함유 건강식품의 제조방법 및 그 제조방법에 의해 제조된 건강식품 | |
| CN109758570A (zh) | 一种对酒精性肝损伤具有辅助保护作用的组合物及其保健品、应用 | |
| KR20200092692A (ko) | 숙취해소용 조성물 | |
| CN104585444A (zh) | 一种牛磺酸植物凉茶饮料 | |
| KR101865819B1 (ko) | 오미자 발효물 및 호두를 함유하는 정제를 포함하는 뇌질환 예방 또는 치료용 약학적 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |